Biocept (STU:B00) Cyclically Adjusted FCF per Share: €-95,358.17 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:B00 Biocept Inc STU:B00
16 GF Score
Price €6.42
View Full Analysis

What is Biocept Cyclically Adjusted FCF per Share?

Biocept STU:B00 16 Cyclically Adjusted FCF per Share is €-95,358.17 as of Jun. 2023. GuruFocus rates STU:B00 with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biocept's adjusted free cash flow per share for the three months ended in Jun. 2023 was €-2.833. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-95,358.17 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-24), Biocept's current stock price is €6.42. Biocept's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 was €-95,358.17. Biocept's Cyclically Adjusted Price-to-FCF of today is .


Biocept  (STU:B00) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biocept Cyclically Adjusted FCF per Share Related Terms


Biocept Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Biocept's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocept Cyclically Adjusted FCF per Share Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -16,295.46 -15,679.85

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18,734.08 -19,096.41 -15,679.85 -16,647.94 -95,358.17

STU:B00 vs IDTA, DIGP, ABMC: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Biocept's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biocept's Cyclically Adjusted Price-to-FCF falls into.


STU:B00
16GF Score
Biocept Inc STU:B00
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocept Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biocept's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-2.833/305.1090*305.1090
=-2.833

Current CPI (Jun. 2023) = 305.1090.

Biocept Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.000 238.031 0.000
201412 0.000 234.812 0.000
201503 -3,100.000 236.119 -4,005.768
201506 -3,478.000 238.638 -4,446.773
201509 -3,348.000 237.945 -4,293.030
201512 -3,952.000 236.525 -5,097.942
201603 -3,634.000 238.132 -4,656.099
201606 -4,068.000 241.018 -5,149.754
201609 -2,700.000 241.428 -3,412.174
201612 -2,147.500 241.432 -2,713.897
201703 -1,807.500 243.801 -2,262.027
201706 -1,663.667 244.955 -2,072.216
201709 -1,531.667 246.819 -1,893.393
201712 -1,288.500 246.524 -1,594.705
201803 -761.000 249.554 -930.412
201806 -633.875 251.989 -767.498
201809 -526.444 252.439 -636.284
201812 -317.467 251.233 -385.547
201903 -141.606 254.202 -169.964
201906 -88.191 256.143 -105.050
201909 -68.610 256.759 -81.530
201912 -54.825 256.974 -65.095
202003 -18.228 258.115 -21.547
202006 -14.050 257.797 -16.629
202009 -12.894 260.280 -15.115
202012 -3.503 260.474 -4.103
202103 0.243 264.877 0.280
202106 3.414 271.696 3.834
202109 -1.384 274.310 -1.539
202112 1.537 278.802 1.682
202203 -1.664 287.504 -1.766
202206 -7.140 296.311 -7.352
202209 -7.894 296.808 -8.115
202212 -7.262 296.797 -7.465
202303 -10.000 301.836 -10.108
202306 -2.833 305.109 -2.833

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-95,358.17 mean?
Biocept (STU:B00) has a Cyclically Adjusted FCF per Share of €-95,358.17 as of Jun. 2023. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biocept and its competitors.
Is Biocept's Cyclically Adjusted FCF per Share too high?
Biocept's current Cyclically Adjusted FCF per Share is €-95,358.17. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's Cyclically Adjusted FCF per Share compare to IDTA and DIGP?
Biocept's Cyclically Adjusted FCF per Share of €-95,358.17 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biocept and its competitors. Biocept's current Cyclically Adjusted FCF per Share is €-95,358.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (STU:B00) has a current Cyclically Adjusted FCF per Share of €-95,358.17. The current Cyclically Adjusted FCF per Share is €-95,358.17. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Biocept (STU:B00), the current Cyclically Adjusted FCF per Share is €-95,358.17 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for STU:B00

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.42
Price